Overview
The GlucoWatch® is one of several types of continuous glucose monitoring systems, also known as CGMS, that is currently available. It measures the blood glucose level by iontophoresis. Electrical current, at a constant, low-level, is conducted through the skin to an area where the level can be measured. This device can provide 3 blood glucose levels per hour for a 12-hour period.
Coverage Guidelines
Tufts Health Plan does not cover the GlucoWatch® continuous glucose monitoring system.
According to the Tufts Health Plan Evidence of Coverage (EOC), a treatment or procedure is considered experimental or investigative “if reliable evidence shows that prevailing opinion among experts regarding the treatment is that more studies or clinical trials are necessary to determine its safety, efficacy, toxicity, maximum tolerated dose, or its efficacy as compared with a standard means of treatment or diagnosis.”
Note: Reliable evidence, as used in this section, shall mean only published reports and articles in the authoritative peer-reviewed medical and scientific literature.
In accordance with the definition above, Tufts Health Plan considers the use of the GlucoWatch® continuous glucose monitoring system to be experimental and investigative. Additional reviews of this treatment or procedure will be performed as new information becomes available.
The GlucoWatch® is one of several types of continuous glucose monitoring systems, also known as CGMS, that is currently available. It measures the blood glucose level by iontophoresis. Electrical current, at a constant, low-level, is conducted through the skin to an area where the level can be measured. This device can provide 3 blood glucose levels per hour for a 12-hour period.
Coverage Guidelines
Tufts Health Plan does not cover the GlucoWatch® continuous glucose monitoring system.
According to the Tufts Health Plan Evidence of Coverage (EOC), a treatment or procedure is considered experimental or investigative “if reliable evidence shows that prevailing opinion among experts regarding the treatment is that more studies or clinical trials are necessary to determine its safety, efficacy, toxicity, maximum tolerated dose, or its efficacy as compared with a standard means of treatment or diagnosis.”
Note: Reliable evidence, as used in this section, shall mean only published reports and articles in the authoritative peer-reviewed medical and scientific literature.
In accordance with the definition above, Tufts Health Plan considers the use of the GlucoWatch® continuous glucose monitoring system to be experimental and investigative. Additional reviews of this treatment or procedure will be performed as new information becomes available.
ليست هناك تعليقات:
إرسال تعليق